Newsfeeds - Spark Newswire

1 minute read

Earnings

Earnings Outlook For Ocugen

Today, 2:48 AM

Ocugen (NASDAQ:OCGN) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that Ocugen will report an earnings per share (EPS) of $-0.08.

OCGN

4 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

Today, 2:48 AM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

BIIB

1 minute read

Ocugen’s Partner COVID-19 Vaccine Covaxin Shows Encouraging Action In Children Below 18 Years

By Vandana Singh

Today, 2:48 AM

Ocugen Inc (NASDAQ:OCGN) announced the publication of positive pediatric Phase 2/3 study results in children aged 2–18 years for COVID-19 vaccine,…

OCGN

1 minute read

News

Article in Nature Microbiology Says Inactivated Whole-Virion Vaccine BBV152/Covaxin Elicits Robust Cellular Immune Memory to Sarscov-2 and Variants of Concern

By Charles Gross

Today, 2:48 AM

https://www.nature.com/articles/s41564-022-01161-5.epdf?sharing_token=MpVlYuz8TA0rxdAzKPCl4dRgN0jAjWel9jnR3ZoTv0Necl0DNKYADOncNjVs7G8t15n3d-5o5UT8C3h7PFGyI5wP-pGcIS0BSNaWdtcbST-tf-1sQ6-vrwJGiB9G1XRaDtivmvCcGn9EPx4TZvISApHl7L3rd1dRpyANfnDr9nQ%3D

OCGN

6 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 2, 2022

By Benzinga Insights

Today, 2:48 AM

ADC

1 minute read

Ocugen Diversifies Its Pipeline With New Cell Therapy Platform

By Vandana Singh

Today, 2:48 AM

Ocugen Inc (NASDAQ:OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous…

OCGN

1 minute read

Ocugen Announces FDA Removes Clinical Hold On Phase 2/3 Clinical Trial For COVAXIN

By Benzinga Newsdesk

Today, 2:48 AM

Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that the U.S. Food and Drug Administration

OCGN

2 minute read

The Daily Biotech Pulse: Limited Use Of JNJ’s COVID-19 Shot, Myovant-Pfizer’s Relugolix Application Delayed, Gain Therapeutics’ Parkinson’s Data

By Vandana Singh

Today, 2:48 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

AIM

6 minute read

Earnings Scheduled For May 6, 2022

By Benzinga Insights

Today, 2:48 AM

Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion.

ABR

48 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 2:48 AM

During Thursday, 849 stocks hit new 52-week lows.

AADI